DECIPHERA PHARMAC. DL-,01DECIPHERA PHARMAC. DL-,01DECIPHERA PHARMAC. DL-,01

DECIPHERA PHARMAC. DL-,01

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.51EUR
Revenue estimate
‪42.82 M‬EUR
Market capitalization
‪1.95 B‬EUR
‪−176.62 M‬EUR
‪148.00 M‬EUR
‪50.23 M‬
Beta (1Y)
1.51

About Deciphera Pharmaceuticals, Inc.

CEO
Steven L. Hoerter
Headquarters
Waltham
Employees (FY)
355
Founded
2003
FIGI
BBG00PZG5HC4
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange DECIPHERA PHARMAC. DL-,01 stocks are traded under the ticker D05.
DECIPHERA PHARMAC. DL-,01 is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
D05 earnings for the last quarter are −0.55 EUR per share, whereas the estimation was −0.58 EUR resulting in a 4.82% surprise. The estimated earnings for the next quarter are −0.53 EUR per share. See more details about DECIPHERA PHARMAC. DL-,01 earnings.
DECIPHERA PHARMAC. DL-,01 revenue for the last quarter amounts to ‪40.97 M‬ EUR despite the estimated figure of ‪37.32 M‬ EUR. In the next quarter revenue is expected to reach ‪41.62 M‬ EUR.
Yes, you can track DECIPHERA PHARMAC. DL-,01 financials in yearly and quarterly reports right on TradingView.
D05 net income for the last quarter is ‪−42.75 M‬ EUR, while the quarter before that showed ‪−46.90 M‬ EUR of net income which accounts for 8.85% change. Track more DECIPHERA PHARMAC. DL-,01 financial stats to get the full picture.
No, D05 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, D05 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DECIPHERA PHARMAC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
D05 reached its all-time high on Feb 13, 2020 with the price of 63.0 EUR, and its all-time low was 6.0 EUR and was reached on Mar 8, 2022.
See other stocks reaching their highest and lowest prices.
As of May 2, 2024, the company has 355.00 employees. See our rating of the largest employees — is DECIPHERA PHARMAC. DL-,01 on this list?
We've gathered analysts' opinions on DECIPHERA PHARMAC. DL-,01 future price: according to them, D05 price has a max estimate of 27.98 EUR and a min estimate of 21.45 EUR. Read a more detailed DECIPHERA PHARMAC. DL-,01 forecast: see what analysts think of DECIPHERA PHARMAC. DL-,01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DECIPHERA PHARMAC. DL-,01 EBITDA is ‪−185.17 M‬ EUR, and current EBITDA margin is −125.12%. See more stats in DECIPHERA PHARMAC. DL-,01 financial statements.